

1/23




FIG. 1A




FIG. 1B

2/23




FIG. 1C




FIG. 1D




FIG. 2A







FIG. 2B

4/23

*FIG. 3A**FIG. 3B*



6/23




FIG. 5A




FIG. 5B




FIG. 5C

7/23




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 6E




FIG. 6F




FIG. 6G




FIG. 6H




FIG. 6I

8/23




FIG. 7

9/23

Geometric Mean of NT-ProBNP Through Week 24 in Groups 1 and 2




FIG. 8

10/23




FIG. 9




FIG. 10

12/23




FIG. 11A





FIG. 11B

14/23



15/23





FIG. 13

Correlation between NT-proBNP level and pVO₂

ESTIMATED CHANGE IN PVO₂ PER
DOUBLING OF LOG₂ (NT_PROBNP)*



*Slope expressed as an absolute value

FIG. 14




FIG. 15




FIG. 16

18/23




FIG. 17

19/23

Treatment Effect on Primary Composite Endpoint by Subgroup




FIG. 18




FIG. 19





FIG. 20

22/23

*FIG. 21A*

23/23

DRX ATPase Rate - 461 and 581




FIG. 21B

SRX ATPase Rate - 461 and 581




FIG. 21C